How to Source Quetiapine Fumarate Extended-Release tablets (XR) for Pharmaceutical Formulation
Quetiapine Fumarate Extended-Release tablets (XR) (Extended-Release tablets (XR), 50 mg, 150 mg, 200 mg, 300 mg, 400 mg) is classified under Antipsychotropic Drugs. It is therapeutically aligned with reference brands such as US: Seroquel®, Seroquel XR®; EU: Seroquel®, Seroquel Prolong®, Quetiapine Teva®. This guide highlights key sourcing factors buyers should consider when procuring high-quality Quetiapine Fumarate Extended-Release tablets (XR) for formulation, R&D, or bulk manufacturing.
1. Regulatory Compliance & Documentation
Ensure suppliers provide:
- ✔ Valid DMF (Drug Master File)
- ✔ COA (Certificate of Analysis) for each batch
- ✔ GMP, ISO, or ICH Q7 compliance certificates
2. Purity, Grade & Specification Matching
Quetiapine Fumarate Extended-Release tablets (XR) must meet exact grade and purity for your dosage form:
- ✔ USP / EP / JP grade verification
- ✔ Particle size distribution check
- ✔ Residual solvent and heavy metal limits
3. Supplier Reliability & Audit History
- ✔ Positive past audit reports
- ✔ Pharma client references
- ✔ Years of proven API manufacturing experience
4. Commercial Terms: Pricing, MOQ & Flexibility
- ✔ Transparent pricing
- ✔ Pilot batch MOQ flexibility
- ✔ Volume-based discounts
5. Lead Time, Inventory & Logistics
Typical lead time for Quetiapine Fumarate Extended-Release tablets (XR) is 4–6 weeks.
- ✔ Emergency dispatch options
- ✔ Regional warehousing
- ✔ Special storage if needed
6. Formulation Support
- ✔ Technical datasheets
- ✔ Sample availability
- ✔ Stability study support
Conclusion
Sourcing Quetiapine Fumarate Extended-Release tablets (XR) is more than procurement—it’s a strategic partnership. With its extended-release tablets (xr) form and 50 mg, 150 mg, 200 mg, 300 mg, 400 mg specification, choosing a compliant supplier ensures consistent quality and regulatory approval. Prioritize documentation, verify compatibility, and build relationships with transparent, reliable suppliers to secure long-term success.
Frequently Asked Questions For Sourcing of Quetiapine Fumarate Extended-Release tablets (XR)
What is the typical lead time for Quetiapine Fumarate Extended-Release tablets (XR)?
Lead times range from 4–6 weeks depending on supplier and region.
Is Quetiapine Fumarate Extended-Release tablets (XR) available in multiple grades?
Yes — common grades include USP, EP, and JP. Verify grade suitability for your dosage form before purchase.
Does Quetiapine Fumarate Extended-Release tablets (XR) require special storage?
It should be stored in a cool, dry place away from direct sunlight.
Is a Drug Master File (DMF) available for Quetiapine Fumarate Extended-Release tablets (XR)?
Yes, a DMF is available for regulated markets upon request. It includes detailed quality, manufacturing, and stability data.
Can I request samples or a pilot batch of Quetiapine Fumarate Extended-Release tablets (XR)?
Yes — pilot batches or samples can be arranged for R&D, stability studies, or formulation trials. MOQ may vary based on region and regulatory scope.
What compliance certificates are available for Quetiapine Fumarate Extended-Release tablets (XR)?
Available documentation may include GMP, ISO 9001, ISO 14001, and ICH Q7 certificates, along with CoA, TDS, and stability data.
Is Quetiapine Fumarate Extended-Release tablets (XR) suitable for regulated markets like US/EU?
Yes — compliant with EU/US/WHO GMP standards and available with regulatory support documentation for filings.
Can Quetiapine Fumarate Extended-Release tablets (XR) be used in fixed-dose combinations?
Yes — many formulations support inclusion in FDCs. Compatibility studies and formulation consultation are available on request.